Zanidatamab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| Trade names | Ziihera |
| Other names | ZW25, zanidatamab-hrii |
| License data |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C5553H8526N1482O1726S36 |
| Molar mass | 124818.10 g·mol−1 |
Zanidatamab, sold under the brand name Ziihera, is a humanized monoclonal antibody used for the treatment of HER2-positive biliary tract cancer.[1][2] It is an IgG-like bispecific HER2-directed antibody.[1][2] Zanidatamab is produced in Chinese hamster ovary cells[1]
The most common adverse reactions include diarrhea, infusion-related reaction, abdominal pain, and fatigue.[2]
Zanidatamab was approved for medical use in the United States in November 2024.[2]
Medical uses
[edit]Zanidatamabis a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.[1][2]
Adverse effects
[edit]The US Food and Drug Administration prescribing information contains a boxed warning for embryo-fetal toxicity.[2]
The most common adverse reactions include diarrhea, infusion-related reactions, abdominal pain, and fatigue.[2]
History
[edit]Efficacy was evaluated in HERIZON-BTC-01 (NCT04466891), an open-label multicenter, single-arm trial in 62 participants with unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer.[2] Participants were required to have received at least one prior gemcitabine-containing regimen in the advanced disease setting.[2]
The US Food and Drug Administration (FDA) granted the application for zanidatamab priority review, breakthrough therapy, and orphan drug designations.[2]
Society and culture
[edit]Legal status
[edit]Zanidatamab was approved for medical use in the United States in November 2024.[2][3]
Names
[edit]Zanidatamab is the international nonproprietary name.[4]
Zanidatamab is sold under the brand name Ziihera.[1]
References
[edit]- ^ a b c d e f https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761416s000lbl.pdf
- ^ a b c d e f g h i j k "FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer". U.S. Food and Drug Administration (FDA). 21 November 2024. Retrieved 23 November 2024.
This article incorporates text from this source, which is in the public domain.
- ^ "Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)" (Press release). Jazz Pharmaceuticals. 20 November 2024. Retrieved 23 November 2024 – via PR Newswire.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
External links
[edit]- "Zanidatamab-hrii". NCI Drug Dictionary.
- "Zanidatamab (Code C130010)". NCI Thesaurus.
- Clinical trial number NCT04466891 for "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |